Intravitreal Bevacizumab for Choridal Neovascularization Secondary to Age-Related Macular Degeneration
To report the short term anatomic and visual acuity response after intravitreal injection of bevacizumab (Avastin, Roche, Rio de Janeiro, Brazil) in patients with choroidal neovascularization secondary to age-related macular degeneration.
|Study Design:||Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Intravitreal Bevacizumab for Choridal Neovascularization Secondary to Age-Related Macular Degeneration|
- Vision change Anatomical changes (Regression of NVE, CNVM, reduction in macular thickness) Electrophysiological changes (ERG, VEP [ Designated as safety issue: Yes ]
- Ocular side effects (infection, RD, IOP rise, cataract)
|Study Start Date:||November 2005|
|Study Completion Date:||November 2008|
|Primary Completion Date:||October 2007 (Final data collection date for primary outcome measure)|
We conducted a retrospective study of 500 eyes with choroidal neovascularization secondary to age-related macular degeneration who were treated with at least two (initial and one month after) intravitreal injection of 1.25 mg bevacizumab and had a follow-up of at least 2 months. Patients underwent Snellen visual acuity testing, optical coherence tomography (OCT) imaging and ophthalmoscopic examination at baseline and follow-up visits.